Our Pricing

Buy Wegovy In Stock UK - All 5 Doses Available Now

Looking to buy Wegovy in stock UK with immediate availability across all five dose strengths? Cured Pharmacy maintains consistent stock of Wegovy 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg pens at £79.00, with free clinical consultations completed in under three minutes and discreet next-day delivery across the UK.

How Wegovy (Semaglutide) Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the natural GLP-1 hormone your body produces after eating, slowing gastric emptying and reducing appetite through direct action on brain receptors that regulate hunger.

In the landmark STEP 1 trial published in the New England Journal of Medicine, participants using semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most significant weight loss outcomes observed in any pharmaceutical trial for obesity treatment. The once-weekly injection format improves adherence compared to daily medications, with clinical data showing sustained weight loss when combined with reduced-calorie diet and increased physical activity [2].

Semaglutide works through multiple mechanisms beyond appetite suppression. It enhances insulin secretion in a glucose-dependent manner, reduces glucagon secretion, and improves glycaemic control — benefits originally harnessed in diabetes treatment before its weight management applications were fully understood [3]. At Cured Pharmacy, our UK-registered prescribers assess your complete medical history to determine if Wegovy is appropriate for your individual circumstances.

Wegovy Dosing Schedule: All Five Strengths Explained

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. The treatment begins at 0.25mg once weekly for four weeks, then increases to 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, before reaching the maintenance dose of 2.4mg weekly [4].

This gradual titration schedule is clinically important. Rapid dose increases correlate with higher rates of nausea, vomiting, and treatment discontinuation in clinical practice [4]. The 16-week escalation period allows your digestive system to adapt to semaglutide's effects on gastric motility. Each pen contains four pre-filled doses at the specified strength, meaning you'll need a new pen each month as you progress through the dosing schedule.

Some patients may require dose adjustments based on tolerability. If you experience persistent gastrointestinal symptoms at any stage, your prescriber may recommend maintaining your current dose for an additional four weeks before advancing. Conversely, patients who reach 2.4mg but don't achieve adequate weight loss after 16 weeks on the maintenance dose should discontinue treatment, as further weight reduction is unlikely [4].

What Happens If You Miss a Dose?

If you miss your scheduled Wegovy injection and fewer than five days have passed, administer the dose as soon as you remember. If more than five days have elapsed, skip the missed dose entirely and resume your normal schedule with the next planned injection [4]. Never double up doses to compensate for a missed injection, as this significantly increases the risk of severe nausea and vomiting. Patients who miss multiple consecutive doses may need to restart the titration schedule from a lower dose to avoid tolerability issues — your prescriber will advise on the appropriate approach based on how long treatment has been interrupted.

Wegovy vs Mounjaro: Clinical Efficacy Comparison

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are once-weekly injectable treatments licensed in the UK for chronic weight management, but they differ in mechanism and clinical outcomes. Wegovy activates GLP-1 receptors exclusively, whilst Mounjaro is a dual GIP/GLP-1 receptor agonist — the first medication to target both incretin pathways simultaneously [5].

Head-to-head data from the SURPASS-2 trial showed tirzepatide produced greater weight loss than semaglutide 1mg in patients with type 2 diabetes, with the highest tirzepatide dose (15mg) achieving 11.2kg average weight reduction compared to 5.7kg with semaglutide [5]. However, direct comparisons between Mounjaro and Wegovy's 2.4mg maintenance dose in obesity populations are limited, as most comparative trials used the lower 1mg semaglutide dose approved for diabetes rather than the higher Wegovy dose.

In clinical practice at Cured Pharmacy, treatment selection depends on individual factors beyond efficacy data alone. Wegovy has a longer UK prescribing history for weight management, with more extensive real-world safety data in obesity populations. Some patients experience better tolerability with one medication over the other due to differences in receptor binding profiles. Your prescriber will consider your medical history, previous treatment responses, and cost considerations when recommending the most appropriate option.

Switching Between Weight Loss Medications

Patients sometimes switch from Wegovy to alternative treatments due to supply issues, tolerability concerns, or inadequate weight loss response. When transitioning between GLP-1 medications, most UK prescribers recommend starting the new medication at its lowest titration dose rather than attempting dose equivalency conversions, as receptor binding characteristics differ between semaglutide and tirzepatide. This approach minimises gastrointestinal side effects during the transition period. If you're considering switching treatments, discuss the appropriate protocol with your prescriber — abrupt changes without proper guidance can compromise both safety and weight loss outcomes.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported adverse events with Wegovy, occurring in over 40% of patients in clinical trials [1]. Nausea affects approximately 44% of users, typically peaking within the first few days after dose escalation and diminishing over subsequent weeks as tolerance develops. Diarrhoea, constipation, vomiting, and abdominal pain are also common, particularly during the titration phase [1].

Practical management strategies can significantly reduce symptom severity. Eating smaller, more frequent meals rather than three large meals helps minimise nausea by avoiding gastric distension. Avoiding high-fat foods, which delay gastric emptying further, reduces the likelihood of feeling uncomfortably full. Staying well-hydrated is essential, particularly if you experience vomiting or diarrhoea. Some patients find that administering their injection in the evening rather than morning reduces daytime nausea, though clinical data doesn't definitively support one timing over another [6].

Rare but serious adverse events require immediate medical attention. Acute pancreatitis has been reported with GLP-1 receptor agonists, presenting as severe persistent abdominal pain that may radiate to the back [3]. Symptoms of thyroid tumours — though only observed in rodent studies, not confirmed in humans — include a lump in the neck, persistent hoarseness, or difficulty swallowing. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [4]. Your prescriber will screen for these contraindications during your clinical assessment.

Who Can Use Wegovy: Eligibility Criteria in the UK

NICE guidelines recommend considering GLP-1 receptor agonists for weight management in adults with a BMI of 35 kg/m² or greater, or 30-34.9 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [7]. Some prescribers may consider treatment at a BMI of 27 kg/m² or above in the presence of significant weight-related health complications, though this falls outside standard NICE recommendations.

Wegovy is contraindicated in several populations. It should not be used during pregnancy or breastfeeding, as weight loss offers no benefit during gestation and semaglutide's effects on foetal development haven't been adequately studied in humans [4]. Patients with a history of severe gastrointestinal disease, including inflammatory bowel disease or gastroparesis, may experience worsening symptoms due to delayed gastric emptying. Those with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome cannot use Wegovy due to theoretical thyroid C-cell tumour risk observed in animal studies [4].

Age considerations also apply. Wegovy is licensed for adults aged 18 and over in the UK, though clinical trials included participants up to age 75. Elderly patients may require more cautious dose titration due to age-related changes in renal function and increased susceptibility to dehydration from gastrointestinal side effects. At Cured Pharmacy, Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and our clinical team review every consultation to ensure prescribing aligns with MHRA guidance and patient safety requirements.

Wegovy and Type 2 Diabetes

Semaglutide was originally developed and licensed for type 2 diabetes management under the brand name Ozempic before its weight management applications were recognised. Patients with type 2 diabetes can use Wegovy, but prescribers must carefully consider existing diabetes medications to avoid hypoglycaemia risk. Semaglutide enhances insulin secretion in a glucose-dependent manner, meaning it stimulates insulin release only when blood glucose is elevated [3]. However, when combined with insulin or sulphonylureas (which work through different mechanisms), the cumulative effect may cause blood sugar to drop too low. Your prescriber may need to adjust your diabetes medication doses when starting Wegovy to maintain safe glycaemic control.

Why Choose Cured Pharmacy for Your Wegovy Prescription

Cured Pharmacy maintains consistent stock across all five Wegovy dose strengths, addressing the supply challenges that have affected UK pharmacies since the medication's launch. Our transparent pricing model shows costs upfront before you complete your clinical consultation — no hidden fees or unexpected charges after your prescriber approves treatment. At £79.00, our pricing reflects our commitment to accessible weight management care without compromising on clinical standards or medication authenticity.

Every prescription undergoes review by UK-registered prescribers who assess your complete medical history, current medications, and weight loss goals. The online consultation takes under three minutes to complete but covers all essential clinical parameters required for safe prescribing. Unlike some online services that use generic questionnaires, our assessment is specifically designed for weight management medications, ensuring your prescriber has the information needed to make an informed clinical decision about your suitability for Wegovy.

We're a fully registered UK pharmacy (GPhC Registration Number 9012511) dispensing only genuine UK-licensed medicines sourced through legitimate pharmaceutical supply chains. All Wegovy pens supplied by Cured Pharmacy come directly from licensed UK wholesalers and include full patient information leaflets, storage guidance, and injection technique instructions. Your medication arrives in 100% discreet packaging with no external markings indicating the contents, and we offer next-day delivery across the UK when you order before our daily cut-off time. If you have questions about your treatment, our pharmacy team is available on (+44) 116 4646009 during business hours to provide clinical guidance and support.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
4. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Medicines.org.uk. Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc
5. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
6. Smits, M. M., & Van Raalte, D. H. (2021). Safety of Semaglutide. Frontiers in Endocrinology, 12, 645563. https://doi.org/10.3389/fendo.2021.645563
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. NICE Technology Appraisal Guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and results may vary between individuals. Weight loss outcomes depend on adherence to treatment and lifestyle modifications including reduced-calorie diet and increased physical activity.